139 related articles for article (PubMed ID: 36384172)
1. Setting limits for N-nitrosamines in drugs: A defined approach based on read-across and structure-activity relationship for N-nitrosopiperazine impurities.
Dos Santos CEM; Dorta DJ; de Oliveira DP
Regul Toxicol Pharmacol; 2022 Dec; 136():105288. PubMed ID: 36384172
[TBL] [Abstract][Full Text] [Related]
2. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).
Kruhlak NL; Schmidt M; Froetschl R; Graber S; Haas B; Horne I; Horne S; King ST; Koval IA; Kumaran G; Langenkamp A; McGovern TJ; Peryea T; Sanh A; Siqueira Ferreira A; van Aerts L; Vespa A; Whomsley R
Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805
[TBL] [Abstract][Full Text] [Related]
3. Presence of nitrosamine impurities in medicinal products.
Sedlo I; Kolonić T; Tomić S
Arh Hig Rada Toksikol; 2021 Mar; 72(1):1-5. PubMed ID: 33787187
[TBL] [Abstract][Full Text] [Related]
4. Genotoxicity assessment of eight nitrosamines using 2D and 3D HepaRG cell models.
Seo JE; Yu JZ; Xu H; Li X; Atrakchi AH; McGovern TJ; Bruno KLD; Mei N; Heflich RH; Guo X
Arch Toxicol; 2023 Oct; 97(10):2785-2798. PubMed ID: 37486449
[TBL] [Abstract][Full Text] [Related]
5. Developing Structure-Activity Relationships for
Cross KP; Ponting DJ
Comput Toxicol; 2021 Nov; 20():. PubMed ID: 34901581
[TBL] [Abstract][Full Text] [Related]
6. Permitted daily exposure limits for noteworthy N-nitrosamines.
Johnson GE; Dobo K; Gollapudi B; Harvey J; Kenny J; Kenyon M; Lynch A; Minocherhomji S; Nicolette J; Thybaud V; Wheeldon R; Zeller A
Environ Mol Mutagen; 2021 Jun; 62(5):293-305. PubMed ID: 34089278
[TBL] [Abstract][Full Text] [Related]
7. Analysis of selected drug formulations for volatile nitrosamines.
Dawson BA; Lawrence RC
J Assoc Off Anal Chem; 1987; 70(3):554-6. PubMed ID: 3610969
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography.
Schmidtsdorff S; Schmidt AH
J Pharm Biomed Anal; 2019 Sep; 174():151-160. PubMed ID: 31174128
[TBL] [Abstract][Full Text] [Related]
9. Estimated Cancer Risks Associated with Nitrosamine Contamination in Commonly Used Medications.
Li K; Ricker K; Tsai FC; Hsieh CJ; Osborne G; Sun M; Marder ME; Elmore S; Schmitz R; Sandy MS
Int J Environ Res Public Health; 2021 Sep; 18(18):. PubMed ID: 34574388
[TBL] [Abstract][Full Text] [Related]
10. Utilisation of parametric methods to improve percentile-based estimates for the carcinogenic potency of nitrosamines.
Thomas R; Thresher A; Ponting DJ
Regul Toxicol Pharmacol; 2021 Apr; 121():104875. PubMed ID: 33556416
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of carcinogenic nitrosamines by rat nasal mucosa and the effect of diallyl sulfide.
Hong JY; Smith T; Lee MJ; Li WS; Ma BL; Ning SM; Brady JF; Thomas PE; Yang CS
Cancer Res; 1991 Mar; 51(5):1509-14. PubMed ID: 1997191
[TBL] [Abstract][Full Text] [Related]
12. Intake of volatile nitrosamines by Chinese residents in different provinces via food and drinking water.
Li X; Bei E; Qiu Y; Xiao H; Wang J; Lin P; Zhang X; Chen C
Sci Total Environ; 2021 Feb; 754():142121. PubMed ID: 32911156
[TBL] [Abstract][Full Text] [Related]
13. Quantum Mechanical Assessment of Nitrosamine Potency.
De S; Thapa B; Sayyed FB; Frank SA; Cornwell PD; Jolly RA
Chem Res Toxicol; 2024 Jun; 37(6):1011-1022. PubMed ID: 38804898
[TBL] [Abstract][Full Text] [Related]
14. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data.
Thresher A; Foster R; Ponting DJ; Stalford SA; Tennant RE; Thomas R
Regul Toxicol Pharmacol; 2020 Oct; 116():104749. PubMed ID: 32777431
[TBL] [Abstract][Full Text] [Related]
15. Clearance of N-nitrosodimethylamine and N-nitrosodiethylamine by the perfused rat liver. Relationship to the Km and Vmax for nitrosamine metabolism.
Graves RJ; Swann PF
Biochem Pharmacol; 1993 Mar; 45(5):983-9. PubMed ID: 8461051
[TBL] [Abstract][Full Text] [Related]
16. Use of less-than-lifetime (LTL) durational limits for nitrosamines: Case study of N-Nitrosodiethylamine (NDEA).
Bercu JP; Masuda-Herrera M; Johnson G; Czich A; Glowienke S; Kenyon M; Thomas R; Ponting DJ; White A; Cross K; Waechter F; Rodrigues MAC
Regul Toxicol Pharmacol; 2021 Jul; 123():104926. PubMed ID: 33862169
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and optimization of a HS-SPME-assisted GC-MS/MS method for monitoring nitrosamine impurities in diverse pharmaceuticals.
Chang SH; Ho HY; Chang CC; Zang CZ; Hsu YH; Lin MC; Tseng SH; Wang DY
J Pharm Biomed Anal; 2022 Nov; 221():115003. PubMed ID: 36095885
[TBL] [Abstract][Full Text] [Related]
18. Risk characterization of N-nitrosodimethylamine in pharmaceuticals.
Paustenbach DJ; Brown SE; Heywood JJ; Donnell MT; Eaton DL
Food Chem Toxicol; 2024 Apr; 186():114498. PubMed ID: 38341171
[TBL] [Abstract][Full Text] [Related]
19. Occurrence and formation potential of nitrosamines in river water and ground water along the Songhua River, China.
Wang X; Liu Z; Wang C; Ying Z; Fan W; Yang W
J Environ Sci (China); 2016 Dec; 50():65-71. PubMed ID: 28034432
[TBL] [Abstract][Full Text] [Related]
20. [Quantitative structure-activity relationship prediction of carcinogenicity of N-nitroso compounds based on category approach and read-across].
Liang QQ; Zheng WW; He GS; Qu WD
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Jul; 51(7):621-627. PubMed ID: 28693087
[No Abstract] [Full Text] [Related]
[Next] [New Search]
